Kwon O, Lee JB, Ahn JM, et al. - Using stent-specific, prospective drug-eluting stents (DES) registries, researchers looked for a possible differential influence of the diabetic status on clinical outcomes with different DES. Overall 17,184 patients, including 11,428 in non-diabetics and 5,756 in diabetics, were analyzed, who received various modern DES, including sirolimus-eluting stents, cobalt-chromium everolimus-eluting stents (EES), platinum-chromium EES, Resolute zotarolimus-eluting stents, and biodegradable-polymer biolimus-eluting stents. At 3-year follow-up, patient-oriented composite endpoint (a composite of all-cause mortality, any myocardial infarction, and any revascularization) was evaluated as the primary outcome. They also assessed target-vessel failure at 3 years. Findings revealed similar 3-year rates of the primary outcome between different types of DES, irrespective of the diabetic status, in this clinical-practice registry study. This implies that clinical response was not different between contemporary DES in patients with or without diabetes.